Travere Therapeutics, Inc.
TVTX
Rankning i aktier
#3499
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Aktiekurs
$52.43
Senast synkroniserad: 2026-10-20
Marknadsvärde
$4.94B
Förändring (1 dag)
3.83%
Förändring (1 år)
88.58%
Land
US
Handel Travere Therapeutics, Inc. (TVTX)
Kategori
Healthcare
Antal utestående aktier för Travere Therapeutics, Inc. (TVTX)
Antal utestående aktier per June 2026: 93.48M
Enligt de senaste finansiella rapporterna och aktiekursen för Travere Therapeutics, Inc. är det aktuella antalet utestående aktier 93.48M. I slutet av December 2023 hade företaget 74.27M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Travere Therapeutics, Inc. (TVTX) från 2009 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 93.48M | 18.49% |
| 2024 | 78.89M | 6.22% |
| 2023 | 74.27M | 16.48% |
| 2022 | 63.76M | 6.56% |
| 2021 | 59.83M | 25.86% |
| 2020 | 47.54M | 12.28% |
| 2019 | 42.34M | 4.74% |
| 2018 | 40.42M | 4.27% |
| 2017 | 38.77M | 4.79% |
| 2016 | 37.00M | 10.24% |
| 2015 | 33.56M | 34.01% |
| 2014 | 25.04M | 76.47% |
| 2013 | 14.19M | 13,200.13% |
| 2012 | 106.70K | -99.89% |
| 2009 | 95.91M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 171.61% |
US
|
|
| 396.00M | 323.62% |
US
|
|
| 478.91M | 412.32% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -33.48% |
NL
|
